Trial · NCT01465152
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
NCT01465152, Phase 4, Completed, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes. Trials, record NCT01465152. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01465152
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
- NCT number
- NCT01465152
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 182 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- metformin, repaglinide
- First posted
- 2011-11-04
- Last updated
- 2017-02-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of % HbA1c (glycosylated haemoglobin) in blood | ||
| Secondary | Change of the mean body mass index calculated as weight in kilograms divided by the square of height in metres | ||
| Secondary | Incidence of clinical and/or biochemistry hypoglycaemia episodes | ||
| Secondary | Incidence of adverse events | ||
| Secondary | Presence of laboratory abnormalities in routine blood analyses | ||
| Secondary | Change of the blood pressure and/or heart rate | ||
| Secondary | Treatment compliance |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01465152
GET https://conductscience.org/api/trials/v1/NCT01465152/registered